Caricamento...
Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis
Biosimilar drugs are highly similar to an originator (reference) biologic, with no clinically meaningful differences in terms of safety or efficacy. As biosimilars offer the potential for lower acquisition costs versus the originator biologic, evaluating the economic implications of the introduction...
Salvato in:
| Pubblicato in: | Pharmacoeconomics |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer International Publishing
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5606961/ https://ncbi.nlm.nih.gov/pubmed/28660473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-017-0529-x |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|